-
Mashup Score: 1ctMoniTR Project - Friends of Cancer Research - 1 year(s) ago
ctDNA for Monitoring Treatment Response Project Quick Links Sign Up for Updates ctMoniTR Project One Pager Project Outcomes ctMoniTR Project Slides ASCO Annual Meeting Poster The ctDNA to Monitor Treatment Response (ctMoniTR) Project is a first of its kind partnership led by Friends of Cancer Research (Friends) to answer the important question: Do changes in…
Source: friendsofcancerresearch.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 27
Listen to this episode from The Late Night Oncology Show on Spotify. [Episódio em Inglês] Para fechar o mês de conscientização dos tumores colorretais, recebemos Dr. Pashtoon Kasi, oncologista clínico com foco em tumores gastrointestinais, professor na Weill Cornell Medicine e autor do estudo BESPOKE CRC, para discutir aspectos relacionados a biópsia líquida em câncer colorretal, incluindo a importância na detecção precoce, determinação de tratamento adjuvante e monitoramento do tratamento no cenário metastático.
Source: open.spotify.comCategories: General Medicine News, Hem/OncsTweet-
Was a delight to be on the @LateNightOnc🎙️🇧🇷 in the company of some wonderful physicians & scientists discussing #ctDNA🧬🩸. 👇🏾Episode available on Spotify. 💡More now than ever it is important to understand the limitations & best use case/scenarios. https://t.co/vMpl6O6o1m https://t.co/iJi6kNzSAY https://t.co/wZSBT6Dvvn
-
-
Mashup Score: 12Blood-based colorectal cancer screening in an integrated health system: a randomised trial of patient adherence - 1 year(s) ago
Objective We evaluated whether people who had not completed a faecal immunochemical test (FIT) for colorectal cancer (CRC) screening would complete a blood-based testing option if offered one during health encounters. Blood-based screening tests for CRC could add to the total number of people screened for CRC by providing another testing alternative. Design Study participants were patients aged 45–75 years at a large, integrated health system who were offered but did not complete an FIT in the prior 3–9 months and were scheduled for a clinical encounter. Individuals were randomised (1:1) to be offered a commercially available CRC blood test (Shield, Guardant Health) versus usual care. We compared 3-month CRC screening proportions in the two groups. Results We randomised 2026 patients; 2004 remained eligible following postrandomisation exclusions (1003 to usual care and 1001 to blood draw offer; mean age: 60, 62% female, 80% non-Hispanic white). Of the 1001 allocated to the blood test g
Source: gut.bmj.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer - 1 year(s) ago
Oncogene – Neoadjuvant botensilimab plus balstilimab response pattern in locally advanced mismatch repair proficient colorectal cancer
Source: www.nature.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 6Mutational Signature Changes in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal - 1 year(s) ago
This study aimed to describe how tissue-based and ctDNA-based mutational concordance, as identified by next-generation sequencing, is affected by chemoradiation
Source: academic.oup.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 133
Nature Medicine – In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 126
Nature Medicine – In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 126
Nature Medicine – In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 87Pan-Cancer Prevalence of Microsatellite Instability-High (MSI-H) Identified by Circulating Tumor DNA and Associated Real-World Clinical Outcomes - 2 year(s) ago
MSI-H identified by ctDNA: prevalence across 21 advanced cancers and outcomes from >700 patients.
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
🗞️Just published @JCOPO_ASCO At the intersection of Liquid Biopsies🔄Precision Medicine Pan-cancer assessment of ✅PLASMA🩸MSI-High and assessment of real-world outcomes. 👉🏾1.4% of 171,881 patients. 💡If shed, 🧬#ctDNA MSI reliable. @OncoAlert @ASCO https://t.co/qoWKZaqEsH https://t.co/J3eZvJvO27 https://t.co/fT90MkoREM
-
-
Mashup Score: 1The emerging role of ctDNA in breast cancer - 2 year(s) ago
Liquid biopsies hold great promise in precision medicine in breast cancer
Source: dailyreporter.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The ctMoniTR project is validating if blood biomarkers, such as #ctDNA can be used to easily determine if a drug is working. By getting this information quickly & in a less invasive way, physicians & patients will understand if the treatment is effective. https://t.co/DYH8eAXXww https://t.co/3vNUEeDwVk